Muva nje, i-China National Medical Products Administration (NMPA) ivumile inkomba entsha ye-Bireociclib, umuthi omusha we-Class 1 owakhiwe ngokuzimela yi-Xuanzhu Biopharmaceutical. Inkomba entsha iwukusetshenziswa kanye ne-aromatase inhibitor njengokwelashwa kokuqala kwe-endocrine kweziguli ezinomdlavuza webele othuthukisiwe we-HR+/HER2. Lokhu kuvunyelwa kuphawula i-Bireociclib njengomuthi wokuqala nowodwa ekilasini layo eShayina ukumboza inkambo ephelele yokwelashwa komdlavuza webele othuthukisiwe we-HR+/HER2—kufaka phakathi ukwelashwa komugqa wokuqala, komugqa wesibili, kanye nomugqa olandelayo—okunikeza inketho entsha yokwelashwa kweziguli emhlabeni jikelele.
Uma wena noma abathandekayo bakho nifuna izindlela zokwelapha umdlavuza webele ezingcono, sicela ukhululeke ukuxhumana ne-International Department of Beijing South Region Oncology Hospital:
- Ucingo: 400-880-3716
- I-WeChat: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
—
**Kusuka Kumugqa Wesibili Kuya Kumugqa Wokuqala: Ukuphumelela "Kwesifundo Esigcwele" kweBireociclib**
I-Bireociclib iyi-CDK2/4/6 inhibitor entsha. Yayivunyelwe ngaphambilini ukusetshenziswa kanye ne-fulvestrant yomdlavuza webele othuthukile oye waqhubeka ngemva kokwelashwa kwe-endocrine, kanye nokwelashwa okukodwa kweziguli ezinesifo sokungalapheki. Ukuvunyelwa kwalesi sibonakaliso esisha kuthuthukisa ukusetshenziswa kwayo ekwelashweni kwe-endocrine komugqa wokuqala, okufeza ngempela ukumbozwa okugcwele kusukela ekwelashweni kokuqala kuya ekwelashweni kokuhlenga komugqa olandelayo.
Lokhu kuvunyelwa kusekelwe emiphumeleni yokuhlaziya yesikhashana yocwaningo lwe-BRIGHT-3. Ucwaningo lukhombisile ukuthi ukusinda okuphakathi kokusinda okungenawo ama-progression (PFS) kweqembu le-Bireociclib kanye ne-AI akukafinyelelwa, okubonisa ukusebenza kahle okuhlala isikhathi eside ngokumangalisayo; uma kuqhathaniswa, i-PFS yeqembu lokulawula yayiyizinyanga ezingu-18.4. Okukhuthaza nakakhulu, izinga le-PFS leminyaka emi-2 eqenjini le-Bireociclib lidlule ku-60%, kanti izinga lokuphendula eliqondile (ORR) lifinyelele ku-63.5%, likhuphukela ku-67.6% ezigulini ezinezilonda ezilinganiswayo. Le datha ikhombisa ukuthi i-Bireociclib okwamanje ibonisa ukusebenza kahle okuphezulu kakhulu phakathi kwemithi efanayo.
**Umklamo Oyinkimbinkimbi Kakhulu: Ukusebenza Nokuphepha Kokulinganisela Okuqondiwe Kakhulu**
Ukuhluka kweBireociclib kusekusebenzeni kwayo okunezinhloso eziningi. Njengesivimbeli esisha se-CDK2/4/6, ayigcini nje ngokuvimbela ngamandla i-CDK4 ne-CDK6 kodwa futhi ivimbela i-CDK2 ne-CDK9 ngasikhathi sinye.
- **Ukunciphisa Ukumelana Nemithi:** Ukusebenza kwe-CDK2 kungenye yezindlela ezibalulekile zokumelana nama-CDK4/6 inhibitors. Ngokuvimbela i-CDK2 ngasikhathi sinye, i-Bireociclib ingavimba ngokuphelele izindlela zokwanda kwamaseli esimila, ngaleyo ndlela ibambezele ukuqala kokumelana nemithi emthonjeni.
- **Ubuthi Obuphansi:** Ubuthi begazi obufana ne-neutropenia yebanga lesi-3/4, evame ukubonwa ngama-CDK4/6 inhibitors endabuko, buncishiswa kakhulu ngokwelashwa nge-Bireociclib. Lokhu kusho ukuthi iziguli zingafinyelela ukubekezelela okungcono kokwelashwa, zinciphise ukuphazamiseka kokwelashwa ngenxa yemiphumela emibi, ngaleyo ndlela ziqinisekise ukuqhubeka kokusebenza kahle.
**Idatha Iqinisekisa Amandla: Impumelelo Ephelele Yochungechunge Lokufunda Olugqamile**
Ukusebenza okuhle kakhulu kweBireociclib akuyona into engavamile kodwa kwakhelwe phezu kwesisekelo esiqinile sochungechunge lwezifundo ze-BRIGHT:
- **Ucwaningo Olukhanyayo-2 (Ukwelashwa Komugqa Wesibili):** I-Bireociclib ehlanganiswe ne-fulvestrant ifinyelele isilinganiso se-PFS sezinyanga ezingu-17.5. Ekuqhathaniseni okungekhona ubuso nobuso, le datha iyona engcono kakhulu.
- **Ucwaningo Olukhanyayo-1 (Ukwelashwa Kokuwodwa Kwemithi Kamuva):** Ezigulini ezelashwe kakhulu, ezithuthuke kakhulu, ukwelashwa okukodwa kwe-Bireociclib kwaholela ku-PFS ephakathi kwezinyanga eziyi-11 kanye nokusinda okujwayelekile (OS) kwezinyanga ezingama-29. Lokhu futhi kuyiphuzu ledatha elihamba phambili emhlabeni wonke, okubonisa ukusebenza kwalo okunamandla kubantu abagulayo abayinselele kakhulu.
**Kungani Kufanele Ukhethe UMnyango Wezizwe Zonke Wesibhedlela Se-Oncology SaseBeijing South Region?**
UMnyango Wezizwe Zonke Wesibhedlela Se-Beijing South Region Oncology uzinikele ekuhlanganiseni ukusungulwa kwemithi okusezingeni eliphezulu emhlabeni wonke nezinsizakusebenza zezokwelapha zaseShayina eziphezulu. Njengomuthi omusha owasungulwa eShayina, ukuvunyelwa kweBireociclib akugcini nje ngokuzuzisa iziguli zasekhaya kodwa futhi kunikeza ithemba elisha ezigulini zamazwe ngamazwe. UMnyango Wethu Wezizwe Zonke uhlinzeka iziguli zakwamanye amazwe ngalokhu:
1. **Ukubonisana Kwabaningi:** Ukuhlolwa kwezimo zezokwelapha kanye nokuthuthukiswa kwezinhlelo ezenzelwe wena yithimba lochwepheshe abaphambili emkhakheni womdlavuza webele.
2. **Ukufinyelela Emithini Emisha:** Ukufinyelela ngesikhathi imithi emisha evunyelwe eShayina yokulwa nomdlavuza, okuhlanganisa neBireociclib.
3. **Insizakalo Egcwele:** Ukusekelwa kwezokwelapha okukodwa, kusukela ekubonisaneni kokuqala kanye nokuqaliswa kohlelo lokwelashwa kuya ekulandeleleni isikhathi eside.
4. **Usizo Lolimi Nokuthutha:** Ukuhumusha kwezokwelapha kochwepheshe kanye nokufinyelela okuzinikele kweziguli zamazwe ngamazwe ukubhekana nezinkinga zezokuthutha.
**Xhumana Nathi Manje**
Uma wena noma amalungu omndeni wakho nilwa nomdlavuza webele othuthukisiwe we-HR+/HER2 futhi nifisa ukwazi ukuthi i-Bireociclib ingaba yindlela yokwelapha efanele yini, sicela uxhumane noMnyango Wezwe Lonke Wesibhedlela Se-Beijing South Region Oncology ngokushesha. Ithimba lethu lochwepheshe lizokunikeza ukubonisana okuningiliziwe kwezokwelapha kanye nosizo lokufuna ukunakekelwa kwezokwelapha eShayina.
- ���� Ucingo: 400-880-3716
- ��� WeChat: 17801183037
- ��� Email: 100085_010@163.com or myimmnet@163.com
Isikhathi sokuthunyelwe: Mashi-06-2026